Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress <i>via</i> enhancing T cell responses and sensitizing cells to gemcitabine
Xin Huang(Beijing Normal-Hong Kong Baptist University), Tao Wen(University of British Columbia), Hang Wu(Wenzhou Medical University), Xuanxin Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Kui Zhu(Sanya University), Dapeng Li(Northwestern University), Tao Wang(Heilongjiang University of Chinese Medicine), Jie Meng, Yuanhao Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaocui Fang(National Center for Nanoscience and Technology), Yanlian Yang(National Center for Nanoscience and Technology)
Cited by 0
Related Papers
Natural Products/Bioactive Compounds as a Source of Anticancer Drugs
|Cancers|2022|327
Sphingosylphosphorylcholine and Lysophosphatidylcholine Are Ligands for the G Protein-coupled Receptor GPR4
|Journal of Biological Chemistry|2001|241
Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-κB pathway
|Respiratory Research|2012|147
Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression
|Biochemical and Biophysical Research Communications|2007|141